A new era for schizophrenia drug development – Lessons for the future DOI Creative Commons
Kiri Granger, Michael Sand,

Sheryl Caswell

et al.

Drug Discovery Today, Journal Year: 2023, Volume and Issue: 28(7), P. 103603 - 103603

Published: May 3, 2023

For many patients and their treating clinicians, the pharmacological management of psychotic symptoms centres on trying to find a regime that balances efficacy quality life-impairing side effects associated with dopamine antagonism. Recent reports positive Phase III study from Karuna Therapeutics indicate first primarily non-dopamine-based treatment for schizophrenia may come market soon potential substantially reduced or differentiated effects. Against background repeated failures, Karuna's success promises desperately needed new option patients. It also reflects some hard-won lessons about methodology drug development.

Language: Английский

Annual Research Review: Psychosis in children and adolescents: key updates from the past 2 decades on psychotic disorders, psychotic experiences, and psychosis risk DOI Creative Commons
Ian Kelleher

Journal of Child Psychology and Psychiatry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 3, 2025

Psychosis in children and adolescents has been studied on a spectrum from (common) psychotic experiences to (rare) early-onset schizophrenia disorders. This research review looks at the state-of-the-art for across psychosis spectrum, evidence community clinical samples of findings risk syndrome research, The also new opportunities capture childhood adolescence, including early intervention, identifies important unanswered questions, points future directions prevention research.

Language: Английский

Citations

1
A new era for schizophrenia drug development – Lessons for the future DOI Creative Commons
Kiri Granger, Michael Sand,

Sheryl Caswell

et al.

Drug Discovery Today, Journal Year: 2023, Volume and Issue: 28(7), P. 103603 - 103603

Published: May 3, 2023

For many patients and their treating clinicians, the pharmacological management of psychotic symptoms centres on trying to find a regime that balances efficacy quality life-impairing side effects associated with dopamine antagonism. Recent reports positive Phase III study from Karuna Therapeutics indicate first primarily non-dopamine-based treatment for schizophrenia may come market soon potential substantially reduced or differentiated effects. Against background repeated failures, Karuna's success promises desperately needed new option patients. It also reflects some hard-won lessons about methodology drug development.

Language: Английский

Citations

14